SCHEMBL1973007

SCHEMBL1973007

COC(=O)c1ccc(-n2nnnc2C(F)(F)F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
HTT P42858 3/20 0.61
HPGD P15428 2/20 0.61
TSHR P16473 5/20 0.48
NPSR1 Q6W5P4 3/20 0.48
LMNA P02545 2/20 0.48
GAA P10253 1/20 0.48
MAPK1 P28482 1/20 0.48
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
KDM4E B2RXH2 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 4/20 0.43
POLB P06746 1/20 0.43
USP2 O75604 1/20 0.43
HSP90AA1 P07900 1/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
TACR1 P25103 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12513443 0.84 TSHR (0.48) ALDH1A1HTTHPGDTSHRLMNA
SCHEMBL1971628 0.82 HPGD (0.49) ALDH1A1HTTHPGDTSHRNPSR1
SCHEMBL6424614 0.80 TACR1 (0.47) ALDH1A1HPGDKDM4ETACR1
SCHEMBL357195 0.79 P2RX3 (0.42) ALDH1A1HTTHPGDKDM4EMAPT
SCHEMBL6262563 0.78 ALDH1A1 (0.66) ALDH1A1HTTHPGDTSHRNPSR1
SCHEMBL11331769 0.78 ALDH1A1 (0.66) ALDH1A1HTTHPGDTSHRNPSR1
SCHEMBL4216728 0.78 SMN1; SMN2 (0.55) ALDH1A1HTTHPGDTSHRNPSR1
SCHEMBL18172378 0.78 ALDH1A1 (0.39) ALDH1A1HTTHPGDLMNAMAPT
SCHEMBL5551503 0.76 ALDH1A1 (0.70) ALDH1A1HTTHPGDNPSR1LMNA
SCHEMBL310917 0.76 ALDH1A1 (0.47) ALDH1A1HTTHPGDLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
EP-2336105-B9 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL (JP) 2014-09-17 EP disclosed
EP-2336105-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL (JP) 2014-02-12 EP disclosed
US-8592454-B2 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-11-26 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B ALDH1A1 3648/4885HTT 244/4885HPGD 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.